Icotinib: efficacy in different solid tumors and gene mutations

Area of Science:

• Oncology
• Pharmacology

Background:

• Icotinib is a first-generation epidermal growth factor receptor (EGFR) inhibitor approved in China for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations.
• EGFR alterations are implicated in various solid tumors, driving cancer growth and progression.

Purpose of the Study:

• To review the efficacy of icotinib in solid tumors characterized by diverse epidermal growth factor receptor alterations.
• To consolidate current understanding of icotinib's therapeutic potential beyond its primary indication.

Main Methods:

• Literature review of studies evaluating icotinib in solid tumors.
• Analysis of clinical data on icotinib's efficacy across different tumor types and EGFR mutation statuses.
• Synthesis of findings related to treatment response and outcomes.

Main Results:

• Icotinib demonstrates approved efficacy in NSCLC with EGFR-sensitive mutations.
• Moderate activity is observed in NSCLC with rare, non-resistant EGFR mutations.
• Icotinib shows potential in esophageal cancer with EGFR amplification or overexpression.

Conclusions:

• Icotinib is a valuable therapeutic option for NSCLC patients with EGFR-sensitive mutations.
• Further investigation into icotinib's role in other EGFR-altered solid tumors is warranted.
• Icotinib's efficacy is linked to specific epidermal growth factor receptor alterations.